评估CYP2D6表型对老年患者弗鲁沃克萨明药代动学的影响,使用生理学基础的药代动力学建模
1College of Pharmacy, Dongguk University-Seoul, 32 Dongguk-Ro, Goyang-si 10326, Republic of Korea.
Pharmaceutics
|February 27, 2026
概括
在老年患者中,可利用CYP2D6基因型优化弗卢沃胺剂量. 这种方法有助于量身定制药物,改善治疗结果,并减少接受黄素的老年人药物不良反应.
科学领域:
- 药物基因组学 药物基因组学
- 老年人药理学 老年人药理学
- 药物新陈代谢 药物新陈代谢
背景情况:
- 老年患者经常表现出可变的药物反应和增加的副作用.
- 在老年人中,CYP2D6的遗传变异可能会影响fluvoxamine的药理动力学.
- 关于CYP2D6表型对老年人fluvoxamine的影响的研究有限.
研究的目的:
- 为了评估CYP2D6表型对老年患者黄素暴露的影响.
- 开发一种基于生理学的药理动力学 (PBPK) 模型,用于老年患者的黄素剂量.
- 根据CYP2D6基因型,为老年人提供最佳的剂量策略.
主要方法:
- 使用了基于生理学的药理动力学 (PBPK) 建模.
- 老年人特定的生理参数被纳入模型.
- 使用年轻人和老年人的临床药理动力学数据验证了PBPK模型.
主要成果:
- 模拟表明,老年人与年轻人之间的稳定状态暴露率是老年人的1.8倍.
- 与广泛代谢剂 (EM) 相比,CYP2D6低代谢剂 (PMs) 的暴露率高出2.1倍.
- 建议的每日剂量:PMs的~50毫克,中间代谢器的50-100毫克,EMs的100毫克,超快代谢器的150-200毫克.
结论:
- 在老年患者中,基因型引导的CYP2D6剂量可能会优化流胺治疗.
- 这种策略有可能提高治疗疗效.
- 尽量减少药物不良反应是这种高风险人群的关键好处.
相关概念视频
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
273
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
273
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
780
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
780
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
299
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
299
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
288
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
288
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
765
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
765
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
284
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
284